Background: Several lines of evidence suggest that inflammatory mechanisms may be involved in the severity and progression of depression. One pathway implicated is the production of prostaglandins via the enzyme cyclooxygenase (COX
S everal lines of evidence suggest an association between activation of the immune system and major depression. Proinflammatory cytokinesnamely IL-6, IL-1β, IFN-γ , and TNF-α-are elevated in individuals with major depression. [1] [2] [3] [4] [5] Levels of prostaglandins such as prostaglandin E2 are also increased in major depression [6] [7] [8] and may reflect depression severity. 9, 10 A recent meta-analysis points to differences between the immune systems of depressed and nondepressed individuals. 11 The high incidence of major depression in inflammatory medical illnesses 12, 13 and in patients undergoing cytokine therapies 5, 14, 15 also suggests a role for inflammation in the etiology and pathogenesis of depression. Furthermore, administration of cytokines and cytokineinducers, such as endotoxin, to rodents can induce sickness behavior, a well-accepted animal model of depression. [16] [17] [18] Important aspects of sickness behavior may be mediated by elevated brain prostaglandin levels. 19 Of particular interest to this study are the immunologic changes in late-life depression. Depression in the elderly is a major public health concern. Major depression affects 1%-4% of the general elderly population, and minor depression affects another 4%-13% of the population. 20 Estimates of late-life depressive syndromes are even higher in medical and nursing home settings, and individuals with cognitive impairment are particularly vulnerable to the disorder. 21 Although the exact mechanism remains unclear, inflammation has been cited as a biologic risk factor for late-life depression. 22, 23 In several recent studies, major depression in later life was associated with increased levels of proinflammatory cytokines, including IL-6, 24-27 IL-1β, 28 ,29 IL-1 receptor antagonist, 29,30 TNF-α, 26 and prostaglandins. 27 Studies of aged mice have yielded similar findings. [31] [32] [33] One inflammatory pathway implicated in major depression is the conversion of arachidonic acid to prostaglandins via the enzyme cyclooxygenase (COX). COX exists in two isoforms: COX-1, which is constitutively expressed and is cytoprotective, 34 and COX-2, which is inducible by cytokines and promotes further inflammation. 35 Both isoforms are expressed in the central nervous system 36 and serve as potential inflammatory mediators. Naproxen is a nonsteroidal anti-inflammatory agent that inhibits both COX-1 and COX-2, while celecoxib selectively inhibits COX-2. COX-2 inhibitors such as celecoxib inhibit prostaglandin E2 production and reduce the production of proinflammatory cytokines. Celecoxib treatment of aging 37 and depressed mice 38, 39 has been shown to reduce inflammation in the brain. Given that inflammation may be involved in late-life depressive syndromes, one possible antiinflammatory target is the COX enzyme and synthesis of prostaglandins.
Not surprisingly, COX inhibitors have been used in the treatment of major depression. Recent studies of celecoxib as an add-on treatment of major depression 40, 41 and for depressed or mixed episodes of bipolar disorder 42 have demonstrated greater response rates in the add-on groups. Augmentation of selective serotonin reuptake inhibitors with acetylsalicylic acid, a strong inhibitor of COX-1, has also shown promising results. 43, 44 We searched for antiinflammatory treatment studies in late-life depression and could not find published studies using COX inhibitors.
Here we present the results of a treatment study, using nonsteroidal anti-inflammatory drugs (NSAIDs) in adults age 70 and older with and without significant depressive symptoms. In the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), 2,528 individuals were randomized to receive celecoxib, naproxen, or placebo. The 30-item version of the Geriatric Depression Scale (GDS) 45 was administered to all participants at enrollment and follow-up visits allowing us the opportunity to study treatment effects on depressive symptoms. We used GDS scores to classify participants at baseline as depressed (GDS >5) or not depressed (GDS ≤5); we Copyright © American Association for Geriatric Psychiatry. Unauthorized reproduction of this article is prohibited.
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Am J Geriatr Psychiatry 20:6, June 2012 then followed GDS scores over time to see whether monotherapy with either naproxen or celecoxib was associated with less severe depressive symptoms. We hypothesized that if COX-2-related inflammatory mechanisms are involved in the severity and progression of depressive symptoms, inhibition of COX-2 would lead to fewer depressive symptoms over time.
METHODS
The methods of the ADAPT study have been detailed in previous publications. 46, 47 Here we summarize aspects of the methods relevant to these analyses.
Design Overview
ADAPT was a randomized, placebo-controlled, double-masked, primary prevention trial for Alzheimer dementia sponsored by the National Institute on Aging (U01 AG15477). ADAPT was conducted at 6 U.S. memory clinics, and recruitment was accomplished primarily via mass mailings to Medicare beneficiaries in surrounding zip codes. Eligible participants were at least 70 years of age and cognitively normal, with a family history of Alzheimer-like dementia in at least one first-degree relative. Enrollment began in March 2001. All participants signed informed consent for participant under oversight of local institutional review boards. 
Procedures
Eligibility of prospective participants was determined using specified health criteria and cutoff scores on an eligibility battery of cognitive tests. At the enrollment visit, baseline cognitive and functional abilities were assessed using the Cognitive Assessment Battery, which included the 30-item GDS administered by self-report and the Modified MiniMental State Exam (3MS-E). 48 The Cognitive Assessment Battery was administered every 12 months thereafter at follow-up visits. Median length of follow-up after treatment assignment was greater than 2 years.
Outcome Assessment
The 30-item GDS was administered to all ADAPT participants at enrollment and follow-up. The GDS discriminates well between groups of normal, mildly depressed, and severely depressed subjects, including physically ill and cognitively impaired individuals. 49, 50 Participants with a baseline GDS score greater than 5 were classified as depressed and those with a GDS score 5 or less as not depressed. The cutoff of 5 of 6 (case/noncase) is indicative of probable depression, 45 with sensitivities and specificities of 75.3% and 77.0%, respectively. 51 
Data Analysis
Outcome analyses followed the modified intention-to-treat principle but included only participants with at least one GDS score in follow-up assessment. By design, active treatments were compared individually with placebo and not with each other. Mean scores in GDS (with 95% confidence intervals [CIs]), as well as percent with significant depressive symptoms, at baseline and then 12, 24, 36, 48, or 60 months following randomization were calculated for each treatment. Longitudinal analyses comparing GDS scores over time by each treatment compared with placebo, controlling for baseline GDS scores, were conducted using generalized estimating regression equations (GEE) to account for correlations of within-person measures. This method provided estimates with CIs of the difference between the active treatment groups and the placebo group averaged across all follow-up times. Analyses were done using SAS version 9.2. The GENMOD routine was used for GEE analysis.
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RESULTS

Study Sample
Of the 2,528 participants enrolled in ADAPT, 2,312 returned for at least one follow-up visit. The flow of these participants from randomization forward is detailed elsewhere. 47 Table 1 shows baseline characteristics by treatment group for all randomized participants and for the subgroup of participants with significant depressive symptoms at the time of enrollment. The median age at randomization was 74.5 years (range: 70-90). More men than women were enrolled (54% versus 46%). Despite significant efforts to recruit minorities, participants were predominantly white (97%). More than three-quarters of the sample enrolled had some college education, with roughly half having earned a college degree. Nearly three-quarters of participants were married upon study entry. The median 3MS-E score was 94, and most participants had a Karnofsky functional rating of 100.
Copyright © American Association for Geriatric Psychiatry. Unauthorized reproduction of this article is prohibited. Table 2 displays mean GDS scores (and 95% CIs) by visit for all 3 treatment groups along with the percent with significant depressive symptoms, that is, GDS >5. At enrollment the celecoxib-, naproxen-, and placebo-assigned groups had comparable mean GDS scores (3.4, 3.2, and 3.3, respectively) and percentages with significant depressive symptoms (19.9%, 18.9%, and 19.5%, respectively). While the proportion of participants with significant depressive symptoms remained similar after baseline, overall the mean GDS scores, if anything, increased slightly, but not significantly, over time in all treatment groups. Over time, mean GDS scores for participants in the active treatment groups did not differ significantly from those in the placebo group. Figure 1 and 2 illustrate the follow-up mean GDS scores (and 95% CIs) for all participants and for those with significant depressive symptoms at baseline, respectively. At enrollment participants with significant depressive symptoms in the celecoxib-, naproxen-, and placebo-assigned groups had mean GDS scores of 9.1, 8.5, and 8.6, respectively. After an initial decrease at the 12-month follow-up, the mean GDS scores stayed fairly constant over time. Table 3 shows the longitudinal effect of each of the two treatments separately relative to placebo on depressive symptoms over time adjusted for covariates. In multivariable modeling, there was no effect of either treatment on follow-up GDS scores. Of the other variables examined, higher baseline GDS scores, a prior psychiatric history, older age, time in the study, and lower cognition interacting with time were all associated with significantly higher follow-up GDS scores (p <0.01).
GDS Score by Treatment Assignment
Significant Depressive Symptoms and GDS Score
DISCUSSION
In this randomized controlled trial of NSAID treatment in more than 2,500 older adults, neither celecoxib nor naproxen improved depressive symptoms over time compared with placebo. In contrast with prior reports suggesting benefit of COX inhibitors as an adjunct in the treatment of younger and middleaged adults with depression, 40-42 these results do not support the hypothesis suggesting a role for inflammation in the etiology and pathogenesis of depression in older adults. Nevertheless, due to study limitations articulated below, these results alone do refute this inflammatory hypothesis.
On the whole, with a mean GDS score of only 3.29 ± 3.33 at baseline, ADAPT participants were not a depressed sample. Such is the nature of recruitment for prevention trials, with healthy volunteers comprising the majority of participants. However, approximately one-fifth had significant depressive symptoms at enrollment, mostly with mild depression. This proportion did not change much over time. Unexpectedly and for unknown reasons, mean GDS scores increased slightly, but not significantly with time in all treatment groups.
Of interest, here are the 449 participants with significant depressive symptoms at the time of enrollment. We interpret their brief initial decrease in GDS scores as a placebo effect. Thereafter, in contrast to trends for the entire sample, their mean GDS scores stayed fairly constant regardless of assigned treatment. The latter finding suggests that depressive symptoms are not alleviated by NSAID treatment.
Copyright © American Association for Geriatric Psychiatry. Unauthorized reproduction of this article is prohibited. Of the variables examined, the factors associated with higher GDS scores over time were as expected: higher baseline GDS scores, a prior psychiatric history (depression or other psychiatric illness), older age, time in the study, and worse baseline cognitive performance interacting with time. Importantly, neither treatment assignment nor worse cognitive performance was associated with higher GDS scores over time.
This study has several strengths. It is the first large-scale randomized trial to examine the effects of NSAIDs on depressive symptoms in later life. Its large sample size provides significant power to detect even small treatment effects on depressive symptoms. In addition, the median length of follow-up of 2 years is longer than previously published studies, the dropout rate was low and participants generally reported good adherence to treatment. 47 Among the study's weaknesses, the sample was almost entirely white limiting generalizability to other demographic groups. Broad screening for depressive disorders using the GDS-30, although a widely used method, may not be as accurate as a clinical interview. However, sensitivity analyses on this point using cutoffs of GDS >6 or GDS >11 post hoc showed similar findings. Furthermore, because the GDS was administered yearly, short-term responses to treatment would have been missed.
Although these findings provide no support for the hypothesis that anti-inflammatory treatments can help late-life depression, they certainly do not refute this hypothesis. Our results assess only the effects of celecoxib and naproxen, each in a single dosage regimen, and they may not apply to other doses or other NSAIDs. As well, the failure here of NSAIDs to ameliorate late-life depressive symptoms does not address their possible utility as adjuncts to other forms of treatment. Finally, this study investigated just one pathway of inflammation, the arachidonic acid cascade and its inhibition at one particular point, the oxidation of arachidonic acid to prostaglandin H2. Non-COX-dependent mechanisms and cytokines may also be important to the pathophysiology of inflammation. Thus, inflammatory mechanisms may yet play a role in late-life depression via some other pathway that remains to be elucidated.
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